Overall rank by patents
#8,277
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView US Corporation
Roche Diagnostics Hematology, Inc.
USPTO PatentsView assignee record — 39 granted patents across 10 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: G01N (INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES).
39
Total patents granted
10
CPC technology areas
22.0
Avg claims per patent
-70%
5-year filing velocity
The verdict
Roche holds 39 US patents across 10 technology areas — rank #8,277 of 50,000 tracked assignees.
- #8,277
- of 50,000 US assignees by volume
- Top 39%
- by Innovation Score (39.1/100)
- 22.0
- avg claims per patent
- -70%
- filing velocity, last 5 yrs
Portfolio overview
Roche Diagnostics Hematology, Inc. has been granted 39 US utility patents between 2015 and 2025, placing Roche Diagnostics Hematology, Inc. at rank #8,277 across all assignees tracked by PlainPatent. This portfolio spans 10 distinct Cooperative Patent Classification (CPC) subclasses, averaging 22.0 claims per patent with primary concentration in G01N (INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES). As a US Corporation, Roche Diagnostics Hematology, Inc. is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 39.1/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 9 grants, compared with 30 in the 2015–2019 window — a -70% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Roche Diagnostics Hematology, Inc.'s 22.0 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while concentration in 10 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Roche Diagnostics Hematology, Inc. against peers pursuing similar technology classes.
How does Roche compare?
Granted US patents 2015–2025 versus the largest corporate holders — this company marked ◀
- Samsung
SAMSUNG ELECTRONICS CO., LTD.
106,890 patents
- International Bus…
International Business Machines Corporation
72,926 patents
- Canon 34,378
Canon Kabushiki Kaisha
34,378 patents
- LG 32,607
LG ELECTRONICS INC.
32,607 patents
- Taiwan Semiconduc… 31,041
TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY LTD.
31,041 patents
- Apple 30,560
Apple Inc.
30,560 patents
- Qualcomm Incorpor… 30,354
QUALCOMM Incorporated
30,354 patents
- Intel 27,498
Intel Corporation
27,498 patents
- Roche Diagnostics… ◀ 39
Roche Diagnostics Hematology, Inc.
39 patents
What this shows Roche holds 39 patents — placing it at rank #8,277 overall, well behind the volume leaders but ahead of the tens of thousands of smaller assignees in the dataset.
Roche's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
39 Top 39% higher than 61% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView — PlainPatent Innovation Score · 2015–2025
USPTO utility patent grants by year · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 10 | 25.6% |
| 2016 | 4 | 10.3% |
| 2017 | 7 | 17.9% |
| 2018 | 4 | 10.3% |
| 2019 | 5 | 12.8% |
| 2020 | 3 | 7.7% |
| 2021 | 2 | 5.1% |
| 2022 | 1 | 2.6% |
| 2024 | 2 | 5.1% |
| 2025 | 1 | 2.6% |
Which technologies does Roche Diagnostics Hematology, Inc. patent most?
Top 10 of 10 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Focused
Claim Depth Complex
Velocity Declining
Frequently Asked Questions
How many patents does Roche Diagnostics Hematology, Inc. hold?
Roche Diagnostics Hematology, Inc. holds 39 US granted patents filed between 2015 and 2025, spanning 10 technology areas.
What is Roche Diagnostics Hematology, Inc.'s Innovation Score?
Roche Diagnostics Hematology, Inc. has an Innovation Score of 39.1 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Roche Diagnostics Hematology, Inc. focus on?
Roche Diagnostics Hematology, Inc.'s top technology area is G01N (INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES) with 33 patents. The company has filed patents in 10 CPC subclasses total.
Is Roche Diagnostics Hematology, Inc.'s patent filing rate increasing or decreasing?
Roche Diagnostics Hematology, Inc.'s recent filing velocity is -70% compared to the prior five-year period. Filing activity has slowed relative to earlier years.
What does claim depth mean for Roche Diagnostics Hematology, Inc.'s patents?
Roche Diagnostics Hematology, Inc.'s patents average 22.0 claims each. This indicates complex, broadly scoped patents that are harder for competitors to design around.
How is the Roche Diagnostics Hematology, Inc. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
Learn More
How to use this portfolio
Roche's 39 grants land it in the top 39% by Innovation Score — but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance — Roche ranks #8,277 of 50,000. Top 50 holders
- Most of this portfolio concentrates in G01N — see who else leads that technology area. G01N leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity — not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Explore the patent dataset
G01N technology
Roche Diagnostics Hematology, Inc.'s primary CPC class — all holders and yearly trends
Top 50 patent holders
See where Roche Diagnostics Hematology, Inc. ranks among the largest US patent assignees
All technology classes
Browse every CPC technology area by patent activity
How the score works
The four dimensions behind the Innovation Score
Related
Data sourced from USPTO PatentsView — official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.
Read our methodology — how this data is sourced, computed, and verified.
Data sources used on this page
- USPTO PatentsView — the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
- Cooperative Patent Classification (CPC) — the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
- USPTO Patent Public Search — the official interface to verify the status of any individual patent. ppubs.uspto.gov
